评估人血小板裂解物作为替代胎牛血清在人脱落乳牙来源干细胞潜在临床应用中的效果。

Evaluation of Human Platelet Lysate as an Alternative to Fetal Bovine Serum for Potential Clinical Applications of Stem Cells from Human Exfoliated Deciduous Teeth.

机构信息

Institute for Stem Cell & Matters, Cell & Matter Corporation, Cheonan 31116, Republic of Korea.

Institute of Tissue Regeneration Engineering (ITREN), Dankook University, 119 Dandae-ro, Cheonan 31116, Republic of Korea.

出版信息

Cells. 2024 May 16;13(10):847. doi: 10.3390/cells13100847.

Abstract

In recent years, there has been a surge in demand for and research focus on cell therapy, driven by the tissue-regenerative and disease-treating potentials of stem cells. Among the candidates, dental pulp stem cells (DPSCs) or human exfoliated deciduous teeth (SHED) have garnered significant attention due to their easy accessibility (non-invasive), multi-lineage differentiation capability (especially neurogenesis), and low immunogenicity. Utilizing these stem cells for clinical purposes requires careful culture techniques such as excluding animal-derived supplements. Human platelet lysate (hPL) has emerged as a safer alternative to fetal bovine serum (FBS) for cell culture. In our study, we assessed the impact of hPL as a growth factor supplement for culture medium, also conducting a characterization of SHED cultured in hPL-supplemented medium (hPL-SHED). The results showed that hPL has effects in enhancing cell proliferation and migration and increasing cell survivability in oxidative stress conditions induced by HO. The morphology of hPL-SHED exhibited reduced size and elongation, with a differentiation capacity comparable to or even exceeding that of SHED cultured in a medium supplemented with fetal bovine serum (FBS-SHED). Moreover, no evidence of chromosome abnormalities or tumor formation was detected. In conclusion, hPL-SHED emerges as a promising candidate for cell therapy, exhibiting considerable potential for clinical investigation.

摘要

近年来,由于干细胞的组织再生和疾病治疗潜力,细胞治疗的需求和研究重点急剧增加。在候选者中,牙髓干细胞(DPSCs)或人脱落乳牙(SHED)由于其易于获取(非侵入性)、多能分化能力(特别是神经发生)和低免疫原性而受到极大关注。为了临床应用,需要仔细的培养技术,例如排除动物源性补充剂。人血小板裂解液(hPL)已成为细胞培养中替代胎牛血清(FBS)的更安全选择。在我们的研究中,我们评估了 hPL 作为生长因子补充剂对培养基的影响,并对在 hPL 补充培养基中培养的 SHED 进行了表征(hPL-SHED)。结果表明,hPL 可增强细胞增殖和迁移,并提高 HO 诱导的氧化应激条件下细胞的存活率。hPL-SHED 的形态表现为体积缩小和伸长,分化能力与 FBS 补充培养基中培养的 SHED(FBS-SHED)相当,甚至超过后者。此外,没有发现染色体异常或肿瘤形成的证据。总之,hPL-SHED 作为细胞治疗的有前途的候选物出现,具有相当大的临床研究潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4be3/11120611/e8d5c9a41a4e/cells-13-00847-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索